Anamorelin Benefits and Effects: How It Helps Improve Appetite and Weight

Anamorelin is an oral selective Ghrelin receptor agonist, mainly used to treat cancer cachexia, and has potential clinical value especially in patients with advanced solid tumors such as non-small cell lung cancer. Cancer cachexia is a metabolic syndrome characterized by loss of appetite, weight loss and muscle loss, which seriously affects the quality of life and prognosis of patients. Anamorelin is a supportive treatment drug developed for such patients.

Anamorelin's mechanism of action is mainly to stimulate the appetite center in the hypothalamus by simulating the physiological function of ghrelin, thereby enhancing the patient's appetite. Ghrelin is a hormone in the human body that promotes appetite. It also promotes the secretion of growth hormone and plays an important role in metabolic regulation. Anamorelin, as its receptor agonist, can not only increase patients' desire to eat, but also improve eating behavior to a certain extent and help patients who have lost appetite due to cancer resume their diet.

In addition to stimulating appetite, anamorelin may also promote weight and muscle mass gain. Studies have shown that anamorelin can stimulate the release of growth hormone and IGF-1 (insulin-like growth factor-1), thereby promoting muscle synthesis and protein storage, and improving the nutritional status and physical performance of cancer patients. Compared with traditional nutritional supplements or appetite-stimulating drugs, anamorelin can effectively improve muscle mass without increasing fat, making it a promising option in the treatment of cancer cachexia.
Overall, anamorelin has significant advantages in improving appetite, maintaining weight and muscle mass in cancer patients, and provides a new supportive treatment option for patients with advanced tumors. The drug has been approved in Japan and other countries for the treatment of cachexia in specific cancer patients. Although it has not yet been widely marketed in mainland China, its clinical trial results internationally are promising, and it is expected to be promoted and applied in more regions in the future to provide strong support for improving the quality of life of cancer patients.
Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/